Hepatic Artery Chemotherapy for Patients With Localized Pancreas Cancer

Pancreatic Ductal Adenocarcinoma Clinical Trial

Official title:

A Window-of-Opportunity Trial Using Neoadjuvant Hepatic Artery Chemotherapy for Patients With Localized Pancreas Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05634720
• Other study ID #: Pro00112285
• Status: Recruiting
• Phase: Phase 4
• Start date: January 2, 2024
• Est. completion date: June 30, 2028

Study information

• Verified date: January 2024
• Source: Duke University
• Contact: Daniel Nussbaum, MD
• Phone: 919-970-8249
• Email: daniel.nussbaum[@]duke.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a window-of-opportunity study which will evaluate the safety and feasibility of single-dose neoadjuvant Hepatic Artery (HA) chemotherapy (FUDR/oxaliplatin) in patients with localized pancreatic ductal adenocarcinoma (PDAC) eligible for surgical resection and systemic chemotherapy. Current standard-of-care therapy for patients with localized PDAC includes surgical resection and six months of systemic chemotherapy. Because the sequence of these treatments (surgery and chemotherapy) is not well established, we will include both patients planned to undergo surgery before chemotherapy, as well as patients planned to receive systemic chemotherapy before surgery. This will allow us to test the safety and feasibility of adding single-dose neoadjuvant HA chemotherapy prior to surgery across the real-world treatment strategies employed in typical clinical practice. Moreover, the window-of-opportunity design is intended to make sure that all patients receive HA chemotherapy in addition to standard-of-care surgery and systemic chemotherapy, so as not to withhold the treatment approach currently associated with best outcomes. The primary endpoint is safety and feasibility, and patients will be followed for 30 days after resection of their primary tumors to assess these outcomes. Following the short-term follow-up period, patients move to long-term follow-up, which will occur every three months after resection of the primary tumor, for a period of up to three years. Long-term secondary endpoints include disease free survival (DFS), liver metastasis-free survival (LMFS), and overall survival (OS).

Description:

This window-of-opportunity study will evaluate the safety and feasibility of single-dose neoadjuvant HA chemotherapy (FUDR/oxaliplatin) in patients with localized PDAC eligible for surgical resection and systemic chemotherapy. Current standard-of-care therapy for patients with localized PDAC includes surgical resection and six months of systemic chemotherapy. Because the sequence of these treatments (surgery and chemotherapy) is not well established, we will include both patients planned to undergo surgery before chemotherapy, as well as patients planned to receive systemic chemotherapy before surgery. This will allow us to test the safety and feasibility of adding single-dose neoadjuvant HA chemotherapy prior to surgery across the real-world treatment strategies employed in typical clinical practice. Moreover, the window-of-opportunity design is intended to make sure that all patients receive HA chemotherapy in addition to standard-of-care surgery and systemic chemotherapy, so as not to withhold the treatment approach currently associated with best outcomes. During an initial screening period (0 to 28 days before the treatment period), informed consent will be obtained and all inclusion/exclusion criteria will be confirmed for participation. Once deemed appropriate for participation, patients will be enrolled and begin study treatment. On Day 1 of the treatment period, patients will undergo standard-of-care diagnostic laparoscopy to confirm the absence of metastatic disease not seen on staging imaging, as well as tissue acquisition (blood and liver biopsies) for pre-specified correlative scientific studies. On Day 2 (±1 day), patients will receive the interventional treatment, which is neoadjuvant HA chemotherapy. On Day 14 (±5 business days), patients will undergo standard-of-care resection of their primary tumor, as well as tissue acquisition (blood, liver biopsies, primary tumor, regional lymph nodes) for pre-specified correlative scientific studies. The primary endpoint is safety and feasibility, and patients will be followed for 30 days after resection of their primary tumors to assess these outcomes. This includes safety evaluations on treatment period Day 1 (diagnostic laparoscopy), Day 2 (±1 day, HA chemotherapy), Day 4 (+2 business days), Day 14 (±5 business days, day of primary tumor resection), every day throughout the perioperative hospitalization, and at outpatient follow-up (30 days ±10 business days after surgery for resection of the primary tumor). Following the short-term follow-up period, patients move to long-term follow-up, which will occur every three months (±20 business days) after resection of the primary tumor, for a period of up to three years. Long-term secondary endpoints include DFS, LMFS, and OS. As mentioned, a biobanking effort is built into this study to support prespecified correlative scientific objectives. This includes acquisition of peripheral blood and liver biopsies at the time of diagnostic laparoscopy (Day 1), acquisition of peripheral blood, liver biopsies, the primary tumor, and regional lymph nodes at the time of resection of the primary tumor (Day 14 ±5 days), and acquisition of peripheral blood at outpatient follow-up appointments. Correlative studies include multisite immune profiling, assessment of the HOMB both before and after HA chemotherapy, and dynamic assessment of ctDNA.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: June 30, 2028
• Est. primary completion date: April 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Patients are eligible to be included in the study only if they meet all of the following

criteria:

1. Histologically or cytologically confirmed diagnosis of PDAC, which is clinically staged as either resectable or borderline resectable after multidisciplinary evaluation.

2. Age >= 18 yo

3. ECOG Performance Status 0-1

4. Eligibility for FOLFIRINOX as determined by medical oncology and multidisciplinary evaluation.

5. Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must use accepted contraceptive methods (abstinence, intrauterine device [IUD], oral contraceptive or double barrier device) during the study and must have a negative serum or urine pregnancy test within 1 week of neoadjuvant HA chemotherapy as well as during adjuvant chemotherapy as per SOC practices.

6. Fertile men must practice effective contraceptive methods during the study, unless documentation of infertility exists.

7. Expected survival >3 months.

8. Adequate laboratory parameters and organ function, namely:

1. Absolute neutrophil count (ANC) = 1.5 x 109/L

2. Platelets = 100 x 109/L

3. Hemoglobin (Hgb) = 8 g/dL

4. Total bilirubin = 1.5 x upper limit of normal (ULN)

5. ALT and AST = 2.5 x ULN

6. Serum creatinine = 1.5 x ULN or creatinine clearance (estimated) = 50 cc/min by Cockroft-Gault Formula (Appendix C)

9. Provide written, informed consent to participate in the study and follow the study procedures. Exclusion Criteria:

Patients will be excluded from the study if they meet any of the following criteria:

1. Hepatic arterial anatomy not amenable to percutaneous access, including any of the following: celiac or superior mesenteric artery occlusion; accessory and replaced left hepatic artery anatomy; accessory right hepatic artery anatomy; middle hepatic artery anatomy; right gastric artery that originates more than 1 cm above the left hepatic artery origin; any other variant anatomy deemed to have a risk of non-target GI infusion; or incomplete hepatic perfusion from a separate left and right hepatic artery.

2. CA 19-9 >500 within 2 weeks of planned surgical resection.

3. Pregnancy or breastfeeding.

4. Not willing to use an effective method of birth control.

5. History of other carcinomas diagnosed within the last two years, except cured non-melanoma skin cancer, curatively treated in-situ cervical cancer, curatively treated localized thyroid cancer, or localized prostate cancer treated curatively with no evidence of biochemical or imaging recurrence.

6. Liver cirrhosis.

7. Prior liver surgery including partial hepatectomy or transplantation.

8. Active hepatitis or unresolved biliary obstruction at the time of diagnostic

laparoscopy, as evidenced by:

1. Total bilirubin > 1.5 x ULN

2. ALT and AST > 2.5 x ULN

9. Recent or current active infectious disease requiring systemic antivirals, antibiotics or antifungals, or treatment within 2 weeks prior to the start of study drug, including acute or chronic active hepatitis B or hepatitis C infection, or uncontrolled HIV/AIDS. Patients with well controlled HIV are permitted. Patients receiving prophylactic antibiotics (e.g., for prevention of urinary tract infection or chronic obstructive pulmonary disease) are eligible.

10. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to the start of study or anticipation of need for major surgical procedure during the course of the study other than surgical resection of the pancreatic tumor.

11. Serious, non-healing wound, ulcer, or bone fracture.

12. History of allogenic hematopoietic stem cell transplantation.

13. Known hepatitis B virus (HBV) infection (e.g., positive hepatitis B surface antigen [HBsAg]) or hepatitis C virus (HCV) infection (e.g., positive HCV ribonucleic acid [RNA]).

14. Chronic treatment with systemic corticosteroids (> 10 mg daily prednisone equivalents) or immunosuppressive medications

• Intermittent steroids (< 10 mg daily prednisone equivalents) may be used on an as needed basis (e.g. for treatment of nausea, anorexia, and fatigue)
• Physiologic replacement doses of steroids due to adrenal insufficiency are permitted in the absence of active autoimmune disease.
• Topical, inhaled, or intra-articular corticosteroids are allowed.

15. Participation in other interventional research protocols during the screening to 30 day follow up time-point.

16. Concurrent severe and/or uncontrolled medical conditions, which may compromise participation in the study, including impaired heart function or clinically significant heart disease

Related Conditions & MeSH terms

• Pancreatic Ductal Adenocarcinoma
• Pancreatic Neoplasms

Intervention

Drug:
• HA Chemotherapy
On Day 1 of the treatment period, patients will undergo standard-of-care diagnostic laparoscopy to confirm the absence of metastatic disease not seen on staging imaging, as well as tissue acquisition (blood and liver biopsies) for pre-specified correlative scientific studies. On Day 2 (±1 day), patients will receive the interventional treatment, which is neoadjuvant HA chemotherapy. On Day 14 (±5 business days), patients will undergo standard-of-care resection of their primary tumor, as well as tissue acquisition (blood, liver biopsies, primary tumor, regional lymph nodes) for pre-specified correlative scientific studies.

Locations

Country	Name	City	State
United States	Duke University Health System	Durham	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Duke University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety of HA Chemotherapy for PDAC	Number of adverse events	30 days postoperatively
Primary	Feasibility of HA Chemotherapy for PDAC	Number of enrolled patients that receive HA chemotherapy followed by planned standard-of-care surgical resection	30 days post-operatively
Secondary	Disease Free Survival	Number of months without disease progression.	3 years post-operatively
Secondary	Liver metastasis-free survival	Number of months without metastasis to the liver.	3 years post-operatively
Secondary	Overall Survival	Number of months until death.	3 years post-operatively